YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Apitegromab MAA resubmission includes alternate fill-finish facility in place of Catalent Indiana LLC (part of Novo Nordisk), in alignment with guidance from EMA Alternate fill-finish facility in MAA is the same site that supported Septemb…
Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
CAMBRIDGE, Mass., September 21, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hir…
Scholar Rock Holding Corporation (NASDAQ:SRRK) secured FDA approval on September 11 for ISEMBYLD, apitegromab-mstn, to treat spinal muscular atrophy in adults and children aged two and older currently receiving survival motor neuron 2 (SMN…
Scholar Rock Holding now carries a slightly higher modelled fair value, shifting from US$59.31 to US$62.06. This places it in line with the low to mid US$60s price targets cited in recent research. Street commentary around the Isembyld app…
Scholar Rock (SRRK) could face some friction during the early commercialization of Isembyld after th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Wall Street street sign in Manhattan financial district] Alexey_Fedoren Scholar Rock (SRRK [https://seekingalpha.com/symbol/SRRK]) shares continued to tumble on Tuesday as Barclays downgraded the Massachusetts-area biotech despite last we…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock for spinal muscular atrophy (SMA) i…
Scholar Rock Holding (SRRK) won early regulatory approval of Isembyld to treat spinal muscular atrop PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Medical researcher in gloves using a tablet ©Adobe Stock Images Scholar Rock Holding Corp (NASDAQ:SRRK) shares rose 9.1% in pre-market trading to $60.45 after the US Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) for the…
Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks f…
[SMA, spinal muscular atrophy, Written on wooden blocks, a rare disease in which, due to a genetic defect, neurons in the spinal cord responsible for muscle contraction and relaxation gradually die.] Andrzej Rostek/iStock via Getty Images…
ISEMBYLD is approved for use in all adults and children ≥2 years of age with SMA who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment ISEMBYLD recommended dose of 10 mg/kg showed a robust, clinically meaningful 2…
Apitegromab for FSHD granted Fast Track and Orphan Drug designations by FDA Dosing underway in Phase 2 FORGE trial; FSHD program expands Scholar Rock's global leadership in myostatin biology across rare neuromuscular diseases FORGE builds…
CAMBRIDGE, Mass., August 27, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its wor…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Scholar Rock Holding stock has delivered an extremely strong multi year return, yet the latest va…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Scholar Rock Holding (SRRK) updated investors after shifting apitegromab's commercial fill finish…
Earlier this week, Scholar Rock announced it has removed Catalent Indiana from all commercial fill-finish roles for apitegromab, with the FDA continuing to review its U.S. BLA using an alternate, previously inspected facility and the compa…
Scholar Rock (SRRK) said Friday that, under guidance from the FDA, it has removed Novo Nordisk's (NV PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Under FDA guidance, Scholar Rock has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA); FDA review o…
Two healthcare players, Scholar Rock Holding Corporation (NASDAQ:SRRK) and Novo Nordisk A/S (NYSE:NVO), find their near-term narratives intertwined over manufacturing compliance. One is smoothly navigating a supply chain hurdle ahead of a…
CAMBRIDGE, Mass., August 14, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hir…
(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biolog…
Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (O…
This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Scholar Rock Holding Corp (NASDAQ:SRRK) has two in…
Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Pres…
CAMBRIDGE, Mass., July 29, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and d…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Scholar Rock Holding (SRRK) stock has drawn fresh attention after recent trading performance, with shares last closing at $49.37 on…
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary duties to sharehol…
July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab CHMP Opinion expected following resolution of Catalent Indiana classification s…
CAMBRIDGE, Mass., July 17, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 118,586 shares of its common stock to eleven newly hire…
CAMBRIDGE, Mass., July 16, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, before the financial markets open. The Company will host a…
(RTTNews) - The following biotech stocks touched a 52-wek high on July 10, 2026, driven by key catalysts like encouraging regulatory updates and quarterly results. American Well Corporation (AMWL) American Well, or Amwell, designs and prov…
Move over, New York and Nasdaq — there's a new stock exchange in Texas. On Monday, the Texas Stock Exchange (TXSE) in Dallas went live — but only for members — as it began test trading of designated securities with live trading set to star…
CAMBRIDGE, Mass., June 22, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and d…
CAMBRIDGE, Mass., June 12, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hire…